Log in to save to my catalogue

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4892372

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and sofosbuvir was associated with a sustained HCV virologic response in 96% of patients.
Globally, an estimated 4 million to 5 million persons are chronically infected with both human immunodefi...

Alternative Titles

Full title

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4892372

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4892372

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1501315

How to access this item